Barclays Capital Gives Equalweight Rating to GlaxoSmithKline (GSK)
GlaxoSmithKline (LON: GSK)‘s stock had its “equalweight” rating restated by analysts at Barclays Capital in a research report issued to clients and investors on Monday. They currently have a $24.86 (1545 GBX) price target on the stock.
GSK has been the subject of a number of other recent research reports. Analysts at Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Thursday. They now have a $29.54 price target on the stock. Separately, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of GlaxoSmithKline in a research note to investors on Monday, October 15th. They now have a $24.24 price target on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline in a research note to investors on Friday, October 12th. They now have a $23.59 price target on the stock.
GlaxoSmithKline opened at 1410.00 on Monday. GlaxoSmithKline has a 52-week low of GBX 1321.00 and a 52-week high of GBX 1556.50. The company’s market cap is £69.231 billion.
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.